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Abstract
Background: Disparities in outcomes associated with race and ethnicity are well documented for many diseases
and patient populations. Tuberculosis (TB) disproportionately affects economically disadvantaged, racial and ethnic
minority populations. Pulmonary impairment after tuberculosis (PIAT) contributes heavily to the societal burden of
TB. Individual impacts associated with PIAT may vary by race/ethnicity or socioeconomic status.
Methods: We analyzed the pulmonary function of 320 prospectively identified patients with pulmonary
tuberculosis who had completed at least 20 weeks standard anti-TB regimes by directly observed therapy. We
compared frequency and severity of spirometry-defined PIAT in groups stratified by demographics, pulmonary risk
factors, and race/ethnicity, and examined clinical correlates to pulmonary function deficits.
Results: Pulmonary impairment after tuberculosis was identified in 71% of non-Hispanic Whites, 58% of non-
Hispanic Blacks, 49% of Asians and 32% of Hispanics (p < 0.001). Predictors for PIAT varied between race/ethnicity.
PIAT was evenly distributed across all levels of socioeconomic status suggesting that PIAT and socioeconomic
status are not related. PIAT and its severity were significantly associated with abnormal chest x-ray, p < 0.0001.
There was no association between race/ethnicity and time to beginning TB treatment, p = 0.978.
Conclusions: Despite controlling for cigarette smoking, socioeconomic status and time to beginning TB treatment,
non-Hispanic White race/ethnicity remained an independent predictor for disproportionately frequent and severe
pulmonary impairment after tuberculosis relative to other race/ethnic groups. Since race/ethnicity was self reported
and that race is not a biological construct: these findings must be interpreted with caution. However, because
race/ethnicity is a proxy for several other unmeasured host, pathogen or environment factors that may contribute
to disparate health outcomes, these results are meant to suggest hypotheses for further research.
Background
Health outcome disparities associated with race and eth-
nicity are well documented for many diseases and
patient populations. While there are a variety of expla-
nations for these effects, they are not fully understood
[1-3]. Socio-economic, biological, cultural, demographic,
and other factors all contribute to an individual’s health
before, during and after illness [1,2,4]. While some con-
tributors to health disparities are well defined the
contribution of biological and gender differences, perso-
nal behaviors, value choices, and race/ethnicity on speci-
fic diseases and their clinical outcomes are not [1,3].
It is well established that tuberculosis (TB) is dispro-
portionately prevalent among economically disadvan-
taged and racial/ethnic minority populations [5-8]. The
health impacts of TB associated with differences in race,
ethnicity, and more primary health risks are incomple-
tely known [5-12]. In a prior study, we measured the
frequency and degree of pulmonary impairment in TB
patients who were treated with standard regimes deliv-
ered by directly observed therapy (DOT) [13]. Spirome-
try-defined pulmonary impairment after tuberculosis
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more common in US born and older patients [13,14].
The study’s sample size did not allow stratified analysis
of PIAT prevalence and severity between race/ethnic
and other patient groups. We expanded our sample to
allow a comparison of PIAT frequency across self-iden-
tified race/ethnicity groups and by socioeconomic status.
Methods
Patients and setting
This was a prospective cohort study of all patients 16
years of age and older receiving treatment for culture-
confirmed pulmonary tuberculosis at Tarrant County
Public Health (TCPH) from July 2005 to December
2009. The population includes all persons with culture-
confirmed pulmonary tuberculosis in Tarrant County,
some of whom also had concurrent extra-pulmonary
tuberculosis. Texas requires all diagnosed TB cases be
reported to the local public health authorities [15].
TCPH is the health authority for an urban county with
a 2010 population of 1,789,900 [15]. TCPH provides
treatment for all persons with TB within this jurisdic-
tion, using universal DOT delivered to the patient’sp r e -
ferred location [15,16]. All patients were treated with
standard 4 drug American Thoracic Society (ATS) and
Centers for Diseases and Prevention Control (CDC)
recommended anti-TB regimens [17]. Patients who had
completed at least 20 weeks of this treatment were
asked to participate in this study of their pulmonary
function. The Institutional Review Board of the Univer-
sity of North Texas Health Science Center at Fort
Worth approved the study; IRB project #24-109. All
subjects gave written informed consent.
Pulmonary function testing
Pulmonary function tests (PFTs) by spirometry were
performed on consenting patients. Spirometry was con-
ducted according to ATS guidelines for maneuver, tech-
niques and quality control using the Spirotouch device
(Spirotouch Spirometry System 086578; Spacelabs Bur-
dick; Deerfield, WI) [18,19]. Patients with a history of
bronchodilator use received nebulized albuterol 15 min
before the test. Consistent results were considered varia-
tion of 5% or less between measurements on three sepa-
rate tests. The best of three consistent results was used
to grade pulmonary function.
Impairment was defined and graded using American
Medical Association (AMA) guides for evaluation of
permanent impairments [20]. Forced Expiratory Volume
in 1 min (FEV1) > = 80%, Forced Vital Capacity (FVC)
> = 80% and FEV1/FVC > 70% of predicted were con-
sidered normal. Other results defined pulmonary
impairment. Impairment was categorized as none, mild
(if FEV1 or FVC was > 60% but < 80%), moderate (if
FEV1 or FVC was 41% to 59%) or severe (if FEV1 or
FVC was < 40%) using an interpretive algorithm from
the AMA [18-20].
Trained research personnel obtained demographic
data from patients at the time of enrolment using a
standardized instrument. Data were double entered into
a Microsoft Office 2003 ACCESS database (Microsoft
Corporation, Redmond, WA. 98052). Subjects self-iden-
tified their race/ethnicity, and were given an option to
identify themselves as Hispanic in accordance with US
federal definitions [21]. Because of their small numbers
we combined self-identified Pacific Islanders, Native
American Indians, and Arabs into one group.
Socioeconomic status was assessed according to estab-
lished methods [22,23] and included (1) highest level of
education attained, (2) employment status at diagnosis,
(3) self-identified occupation, and (4) estimate of house-
hold income. Education was categorized into quartiles of
years < 12, 12, 12 to 15 and > 16 years. Similarly, area-
median household income, derived from census-tract
ZIP codes of the patient’sh o m ea d d r e s s ,w a sd i v i d e d
into quartiles of < $27,250, $27,251 to $37 180, $37,180
to 52,777 and > $52,778; ranges comparable to pub-
lished data from US TB patients [5,24]. Homeless per-
son who did not report income were treated as missing
data. We scored patients’ occupations using standard
methods and correlated them to levels of education
[22,23,25]. Occupational status was ranked according to
prestige [22,23,25]. Education was then used as a proxy
for socioeconomic status [23].
Time to beginning TB treatment, defined as the time
from self-reported onset of symptoms to beginning
tuberculosis therapy, was measured to give insight into
patient-related factors associated with accessing health-
care [1]. Ever smokers were patients who gave a history
of current or past cigarettes smoking. Lifetime volume of
cigarette exposure was estimated using pack-years. Expo-
sure to solid fuel smoke (biomass exposure) and duration
of biomass exposure was compared between groups.
We correlated radiographic abnormality with pulmon-
ary function using a validated scoring rubric derived
from published sources (Table 1) [26]. An experienced
physician (SEW) read the baseline chest x-rays taken
during therapy and follow-up chest x-rays taken after 20
weeks of treatment. TB disease site was classified as
“pulmonary only” or “both pulmonary and extra pul-
monary. Observed abnormalities, cavitation, and infiltra-
tion were standardized and scored using the rubric. The
summed total score was correlated with observed pul-
monary function.
Statistical analysis
Parsimonious multivariate logistic regression models
were constructed and analyzed for the full sample and
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racial/ethnic group. Both age and smoking have been
shown to independently exacerbate pulmonary func-
tion decline so were included in all multivariate mod-
els [27-29]. The median age at which impairment and
moderate/severe impairment occurred among the
racial/ethnic groups were compared using Kaplan-Meir
methods. Comparison between groups was performed
using Chi-Square or Fisher’se x a c tt e s t sa n d / o ra n a l y s i s
of variance (ANOVA) plus the Kruskal-Wallis tests
when appropriate. Analysis was performed using SPSS
version 12 for Windows (SPSS Inc; Chicago, IL) and
GraphPad Prism version 5 (GraphPad Software; La
Jolla, CA).
Results
Between July 2005 and December 2009, 362 patients
with culture confirmed pulmonary tuberculosis were
reported to Tarrant County Health and were eligible for
study enrolment (Figure 1). Of these, 320 (88%) were
enrolled. Sixty-nine (22%) self-identified as non-Hispanic
White, 85 (27%) as non-Hispanic Black, 81 (25%) as
Asian, 82 (26%) as Hispanic and 3 (0.9%) were com-
bined as “other” racial/ethnic group. The 3 subjects in
the “other” racial/ethnic group were all male and
included two with mild impairment and one non-
impaired and were excluded from further analysis.
TB disease type and site, and patients’ access to TB
care was similar between race/ethnicity (Table 2). There
were significantly different demographic and clinical
characteristics between race/ethnicity (Table 2). HIV
infection was significantly higher among non-Hispanic
Blacks and level of education significantly lower among
Hispanics compared to non-Hispanic Whites. Clinical
and demographic characteristics, including age and
smoking of US-born were significantly different from
those who were foreign-born. Both proportion of ever-
smokers and level of lifetime cigarette use was signifi-
cantly higher among Whites (p < 0.001 for both mea-
sures) than other groups (Table 2).
The distribution of pulmonary impairment after tuber-
culosis (PIAT) and its severity among racial/ethnic
groups, by smoking status andb ys o c i o e c o n o m i cs t a t u s
is shown in Figures 2, 3, and 4, respectively. PIAT was
more frequent among non-Hispanic Whites compared
to other race/ethnic groups (p < 0.001),a n dw a sm o r e
severe (p = 0.001) (Figure 2). Pulmonary impairment
was identified in 71% of non-Hispanic Whites, 58% of
non-Hispanic Blacks, 49% of Asians and 32% of Hispa-
nics. PIAT frequency was significantly higher among
non-Hispanic Whites compared to other racial/ethnic
groups in both ever-smokers and never-smokers, (p <
0.0001) (Figure 3).
The distribution of employment, income, occupation,
and education data among subjects was similar to that
reported for other US TB patients (9-11). Education and
income were significantly correlated (Pearson’sc o r r e l a -
tion coefficient (r) = 0.21, p < 0.001). When occupa-
tional status was ranked according to prestige, it also
significantly correlated with both education and income
Table 1 Rubric to standardize chest radiographic findings
Findings Score
Abnormal Appearance
No 0
Yes 1
Cavitation
None 0
Cumulative diameter less than 2 cm 1
Cumulative diameter 2 to 4 cm 2
Cumulative diameter greater than 4 cm 3
Extent and pattern of infiltrating lesions
None 0
Occupy less than 25% of thoracic cavity 1
Occupy 25 to 49% of thoracic cavity 2
Occupy more than 50% of thoracic cavity 3
Miliary pattern 1
362 (100%) PTB patients  
  Culture confirmed PTB seen at Tarrant County TB clinic 
during study duration 
42(12%) PFT not done 
  23 died prior to 20 
weeks 
  14 transferred to other 
jurisdictions prior to 
enrolment in study 
  4 incarcerated 
  1 had myopathy 
320 (88%) Acceptable PFT data analyzed 
  320 Pulmonary Tuberculosis 
o  69 (22%) White 
o  85 (27%) Black 
o  81 (25%) Asian 
o  82 (26%) Hispanic 
o  3 (0.9%) Other – excluded in further analysis* 
Figure 1 Study enrolment.
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tively). PIAT prevalence was evenly distributed across all
levels of socioeconomic status: when the highest level of
education attained was used as a proxy for socioeco-
nomic status (Figure 4).
The median “time to beginning TB treatment” for
non-impaired persons was 62 days (interquartile range
[IQR] was 12-110); 93 days for mildly impaired persons
(IQR 61-110), 138 days for moderately impaired subjects
(IQR 32-271), and 37 days for severely impaired subjects
(IQR 12-60). There was no significant association
between race/ethnicity and time to beginning TB treat-
ment, (p = 0.978) (Table 2). Similarly, no association
between time to beginning treatment and PIAT was
observed (p = 0.058) (data not shown).
We obtained baseline chest x-ray results for 99% of
subjects (n = 314), and for 90% (n = 254) of subjects
after either 20 weeks or at therapy completion. Pulmon-
ary impairment was significantly (p < 0.001) correlated
with the presence and magnitude of abnormal chest x-
ray findings for both baseline (Spearman’s correlation
coefficient (r) = 0.4), and subsequent readings, (r =
0.42). Figure 5 shows the distribution of a standardized
severity index among subjects with pulmonary impair-
ment identified by spirometry.
In univariate analysis race/ethnicity, age and US-birth
were significantly associated with PIAT (Table 3). The
likelihood of PIAT increased by 2% (95% confidence
interval [CI] 1, 3) for each 1 year increase in age. PIAT
was 2.3 times more common (95% CI 1.46, 3.61) in US-
born than foreign-born subjects. Race/ethnic groups and
foreign birth were correlated: Spearman’s r = 0.69, p<
0.001.
In a multivariate analysis that controlled for potential
demographic and clinical confounders; the only signifi-
cant predictor for PIAT was non-Hispanic White race/
ethnicity, among whom PIAT prevalence was 3 times
greater (95% C.I. 1.18, 8.40). Since race/ethnic group
and foreign birth were significantly correlated, and to
avoid confounding, separatem u l t i v a r i a t er e g r e s s i o n
models were constructed and are shown in Tables 4 and
5. Risk factors for impairment were variable between
Table 2 Demographic and clinical characteristics of 317 patients with pulmonary tuberculosis (TB) included in the
analysis
Non-Hispanic White Non-Hispanic Black Asian Hispanic
n = 69 n = 85 n = 82 n = 81 p-value
Demography
Male 58 (84) 54 (64) 58 (71) 52 (64) 0.023
US-born 66 (96) 62 (73) 4 (5) 11 (4) < 0.001
Foreign-born 3 (4) 23 (27) 78 (95) 70 (86)
Age (mean[SD]) years 54.33 (13.10) 43.71 (13.51) 44.91 (16.61) 45.95 (15.81) < 0.001
Clinical
HIV positive 5 (7) 15 (18) 3 (4) 7 (9) 0.052
Ever-Smokers n(%) 56 (81) 44 (52) 35 (43) 39 (48) < 0.001
Smoking volume(mean[SD]) pack-years 32.68 (39.56) 8.19 (15.48) 5.52 (9.50) 4.67 (11.78) < 0.001
Biomass Smoke
Exposed n (%) 5 (9) 10 (15) 29 (45) 28 (38) 0.001
Biomass Smoke Exposure duration
(mean [SD]) years 0.80 (3.26) 2.52 (7.38) 6.94 (12.54) 7.09 (14.27) 0.001
FVC (% predicted [SD]) 77.54 (23.70) 78.69 (19.05) 82.09 (19.10) 90.15 (21.19) 0.001
FEV1 (% predicted[SD]) 71.12 (24.30) 76.98 (22.69) 82.85 (19.54) 91.83 (23.03) < 0.001
FEV1/FVC (% [SD]) 73.13 (13.48) 81.11 (13.35) 84.01 (9.75) 85.26 (10.01) < 0.001
BMI (mean[SD]) 21.23 (5.24) 23.07 (4.58) 22.32 (4.90) 25.08 (8.62) < 0.001
Disease site and pattern
PTB only 66 (96) 75 (88) 76 (93) 75 (93) 0.39
PTB and EPTB 3 (4) 10 (12) 6 (7) 6 (7)
Pattern of Impairment
Restrictive 33 (68) 34 (69) 30 (75) 21 (81) 0.571
Obstructive 8 (16) 4 (8) 3 (8) 3 (11)
Mixed 8 (16) 11 (23) 7 (17) 2 (8)
Access (median [IQR]) Days to Begin TB Treatment 63 (183) 65 (130) 93 (157) 80 (103) 0.978
n(%) denotes counts and column percentage, unless indicated otherwise; mean[SD] = mean and standard deviation; median[IQR] = median and inter-quartile
range. BMI body mass index (kg/m
2); EPTB extra-pulmonary TB; HIV human immunodeficiency virus; FEV1 force expiratory volume in 1 second; FVC forced vital
capacity. Three patients designated ‘other’ racial group who were enrolled in study were not included in analysis.
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Page 4 of 10race/ethnicity, with age independently predicting impair-
ment in non-Hispanic Whites and non-Hispanic Blacks
(Table 4). Smoking was associated with three fold (95%
CI 1.15, 7.85) increased risk for impairment among
Asians, but was not predictive for impairment among
non-Hispanic Whites (Table 4, Figure 3). Table 5 shows
the multivariate regression model containing age, smok-
ing and race/ethnicity of 144 US-born persons. In the
model, only non-Hispanic White race/ethnicity and age
Figure 2 Comparisons of frequency and severity of pulmonary
impairment between 317 self-identified racial and ethnic
groups comprising 69 non-Hispanic Whites, 85 non-Hispanic
Blacks, 82 Asians and 81 Hispanics. Figure 2 demonstrates that
proportions impaired and the severity of impairment significantly
varies between racial/ethnic groups; specifically both impairment
frequency and severity was significantly higher among Whites
compared to non-Whites.
Figure 3 Comparison of the frequency of pulmonary
impairment among all self-identified racial groups by country
of birth and smoking status.
Figure 4 Comparisons of the frequency and severity of
pulmonary impairment among patient with different
socioeconomic status. Figure 4 shows that proportions impaired
and the severity of impairment does not vary with increase in
socioeconomic status.
Figure 5 Distribution and severity of lung damage and
baseline chest x-ray (first). Distribution and severity of lung
damage at subsequent chest x-ray (second).
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PIAT increased 5% (95CI 2.0, 8.1) per year of age.
Onset of age-related lung function decline is variable
[19,30,31]; however, for this study cohort onset of
impairment was related to the age at which the different
race/ethnic groups acquired tuberculosis. Consequently,
the risk for moderate or severe pulmonary impairment
is significantly higher among older Whites compared
with non-Whites. As an example, the median age was
51 years for non-Hispanic Blacks, 59 for Whites, 56 for
Asians and 71 years for Hispanics (Figure 6). Similarly,
the probability for developing moderate to severe
impairment was higher in non-Hispanic Blacks of
younger age groups compared to other race/ethnic
groups (Figure 6, panel B). The median age for non-His-
panic Blacks was 63 and that for non-Hispanic Whites
was 72, p = 0.0239. The hazard ratio [HR] was 0.45
(0.22, 0.90).
Discussion
In the U.S., racial/ethnic minorities and foreign-born
persons face disparate risks for TB infection and higher
levels of poor TB disease outcomes, including mortality
[5-9]. We analyzed the relationship between race/ethni-
city and PIAT in a cohort with culture-confirmed pul-
monary tuberculosis that had completed a minimum of
20 weeks of therapy. We found that self-identified non-
Hispanic White TB patients had disproportionately
more frequent and severe pulmonary impairment
Table 3 Unadjusted odds ratio for some pulmonary
impairment
OR (95% C.I) p-value
Race < 0.001
Whites 5.18 (2.58, 10.42)
Blacks 2.88 (1.53, 5.43)
Asian 2.02 (1.07, 3.81)
Hispanics (reference) **
Access
Days to Begin TB treatment
(days) 1.00 (1.00, 1.01) 0.098
Demographic and clinical characteristics
Male 1.36 (0.84, 2.21) 0.207
Females (reference)*
US-born 2.30 (1.46, 3.61) < 0.001
Foreign-born(reference)*
Ever-Smokers 1.00 (0.64, 1.56) 0.997
Never-Smokers (reference)*
Biomass Smoke Exposure 1.33 (0.77, 2.28) 0.308
No Biomass Smoke Exposure (reference)*
Smoking Volume (pack-year) 1.01 (1.00, 1.03) 0.007
Age (years) 1.02 (1.01, 1.03) 0.031
BMI (kg/m2) 0.97 (0.93, 1.01) 0.087
Socioeconomic Status
Education
Some Education (< 12 years)(reference)* ** 0.470
High School Graduate (12 years) 1.46 (0.86, 2.49)
Some College (13 - 15 years) 1.33 (0.67, 2.64)
College Graduate (16 or more year) 1.33 (0.64, 2.78)
Occupation
1 (most prestigious) ** 0.411
2 1.17 (0.52, 2.67)
3 1.68 (0.90, 3.14)
4 (least prestigious) 1.41 (0.78, 2.56)
Area-median household income
< US$27 270 (reference) ** 0.408
US$27 271 - 37 180 0.82 (0.46, 1.46)
US$37 181 - 52 777 0.76 (0.40, 1.44)
US$52 777 1.55 (0.82, 2.92)
BMI body mass index (kg/m
2); OR odds ratio; CI confidence interval
Table 4 Predictors for pulmonary impairment in all 69 Whites, 85 Blacks, 82 Asians and 81 Hispanics with pulmonary
tuberculosis
Non-Hispanic Whites Non-Hispanic Blacks Asians Hispanics
Age (years) 1.06 (1.01, 1.11)* 1.04 (1.00, 1.08)* 0.98 (0.95, 1.01) 1.02 (0.99, 1.05)
US-born † 27.89 (1.02, 766.08)* 0.98 (0.31, 3.06) 0.28 (0.03, 3.08) 1.07 (0.27, 4.17)
Ever Smokers ‡ 2.68 (0.48, 14.98) 1.09 (0.38, 3.11) 3.0 (1.15, 7.85)* 1.02 (0.39, 2.64)
Cox & Snell R-Square 0.12 0.06 0.12 0.02
Chi-Square (p-value) 0.029 0.156 0.018 0.624
*p < 0.05; † Reference = Foreign-born; ‡ Reference = Never Smokers; OR odds ratio; CI confidence interval
Table 5 Predictors for pulmonary impairment in 144 US-
born patients with pulmonary tuberculosis
OR (95%CI) P-value
Age (years) 1.05 (1.02, 1.08) 0.001
Ever-Smokers* 1.77 (0.73, 4.29) 0.208
Non-Hispanic Whites † 4.94 (1.13, 21.63) 0.034
Non-Hispanic Blacks † 3.51 (0.81, 15.12) 0.093
Asians † 0.95(0.05, 18.57) 0.971
Constant 0.04 0.003
Comparison groups; *Ever-Smokers versus Never-Smokers; † Hispanics; OR
odds ratio; CI confidence interval; The patients whose race/ethnicity was
designated ‘other’ are excluded in this analysis
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ratio (OR) of 3.15. These differences persist despite con-
trol for the effects of age, body mass index, smoking,
access to medical treatment, foreign birth and socio-eco-
nomic status. Among the potential explanatory variables
analyzed, only age and race/ethnicity were significant
predictors for impairmenti nU Sb o r np e r s o n s .T h e s e
data demonstrate a previously unrecognized disparate
negative health impact to specific populations of TB
patients.
Current U.S. policy does not consider older adults
high-priority candidates for testing and treatment of
Figure 6 Hazard ratios for different racial groups in developing some pulmonary impairment (Panel A.) and moderate or severe
pulmonary impairment (Panel B) with increase in age. The median ages for panel A are; non-Hispanic Whites 58 years, non-Hispanic Blacks
51 years, Asians 57 years and Hispanics 68 years. For panel B the median age for non-Hispanic Whites is 72 and that for non-Hispanic Blacks is
63.
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disease [17,32]. These recommendations are based on
the potential for adverse drug events associated with
LTBI treatment. Predictors for PIAT varied between
race/ethnic groups and by country of birth. We found
the likelihood for PIAT to increases by an average 5%
for each additional increase in age for US-born patients
(Table 5; Figure 6). NHANES data showed that poorer
lung function is also associated with poor clinical out-
comes including premature death [30,33]. This together
with our findings suggests that moderate to severe PIAT
may also be associated with earlier mortality. Future ver-
sions of LTBI treatment guidelines should consider
reduction of tuberculosis burden from preventing PIAT
as an additional treatment benefit.
Cigarette smoking, an established cause of pulmonary
impairment, was significantly more prevalent among
non-Hispanic Whites compared to other racial/ethnic
groups. The proportion of non-Hispanic Whites
impaired among never-smokers was 70% compared to
78% among ever-smokers. PIAT was more frequently
encountered among non-Hispanic Whites compared to
other racial/ethnic groups (p < 0.001),a n dw h e n
encountered was more likely to be severe (p = 0.001)
(Figure 2) even after controlling for age and smoking
(Figure 3, Tables 4). While there were more non-Hispa-
nic Whites who smoked our data shows this difference
is not sufficient to explain the more severe impairment
found in non-Hispanic Whites.
Previous studies have investigated pulmonary sequelae
of TB from a number of perspectives, but these are not
readily generalized to US populations [31,34-37]. Poh et
al evaluated patients hospitalized for treatment with
non-rifampin chemotherapy regimens and identified
older age, disease severity at presentation and heavy
smoking as predictors for pulmonary impairment [36].
A population-based study from Latin America demon-
strated that older age and repeated TB disease were
associated with pulmonary impairment [31]. Two South
African studies of patients receiving inpatient treatment
[34,37] similarly demonstrated that repeated TB disease
significantly increased risks for pulmonary impairment.
Race/ethnicity was not explored in these studies
[31,34,37. Despite management with best currently avail-
able therapy for tuberculosis we identified some PIAT in
over half (52%) of patients and severe PIAT, in which
less than 50% of personal lung function remains, in
almost 1 in 10 patients (9%). Prevalence and severity of
PIAT were not associated with diagnostic or treatment
delay, suggesting that it occurs early among those with
TB. Therefore, strategies to mitigate PIAT must primar-
ily rely on prevention of active TB.
Our study failed to detect association between socioe-
conomic status and pulmonary impairment. This was an
unexpected and novel finding. Poorer health outcomes
are consistently associated with low socioeconomic sta-
tus [1,5,23]. Despite Hispanics’ lower socioeconomic sta-
tus in our study cohort, and their higher TB incidence
rates relative to other racial/ethnic groups in the US [5];
they enjoyed apparent protection against pulmonary
impairment compared to other racial/ethnic groups.
This finding supports what has been called the “healthy
Hispanic Paradox,” in which Hispanics experience dis-
proportionately greater life expectancy relative to other
racial/ethnic groups [38,39]. Equity in health care access
within the study area allowed by the public treatment of
TB may explain health outcomes’ independence from
socioeconomic status.
There are several areas within our study vulnerable to
ascertainment bias: such as the fact that race/ethnicity
was self-reported, identification and grading of pulmon-
ary impairment was biased towards an obstructive pat-
tern and that the chest x-ray grading of impairment
lacks consensus of standardization. Both race and ethni-
city are contextual, mutually contradictory and usually
assume socially defined constructs with no biologic basis
such that even the definitions used by U.S. federal agen-
cies change with every 10-year census [2,40]. Even
though mixed race/ethnicity is rare among self-identified
non-Hispanic Whites, the US Hispanic population has a
heterogeneous ethnic ancestry comprising of American
Indian, European and African origins [41]. In addition,
30% of self-identified US-born Blacks consider them-
selves of mixed race [41,42]. As a result, the true effects
of race/ethnicity on health outcomes may be difficult to
clearly distinguish and are subject to confounding.
Indeed, AMA grading is biased towards impairment that
is obstructive in nature; hence patients with restrictive
patterns might be under-represented in these estimates
[18-20]. Given these limitations, it cannot be excluded
that the findings reflect different phenotypic disease
entities among different groups, of which some might
be influenced by smoking and some not.
Conclusion
In conclusion, we found that pulmonary TB patients,
who self-identified as non-Hispanic White, had more
prevalent and more severe pulmonary impairment. The
risk for pulmonary impairment remained after several
factors such as smoking and socioeconomic status were
controlled. Since race/ethnicity was self reported and
race is not a biological construct, these findings must be
interpreted with caution. However, because since race/
ethnicity is a proxy for several other unmeasured host,
pathogen or environment factors that may contribute to
disparate health outcomes, these results are meant to
suggest hypotheses for further research. Nevertheless, if
these findings are confirmed among other populations
Pasipanodya et al. BMC Public Health 2012, 12:119
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Page 8 of 10in other locations, they suggest that the decision-making
thresholds of risk of TB prevention strategies should be
reconsidered to include the benefits of preventing PIAT.
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